Summary
38.81 0.44(1.15%)10/04/2024
Glaxosmithkline plc (GSK)
Glaxosmithkline plc (GSK)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.15 | -4.64 | -12.29 | -0.09 | -5.03 | 8.65 | 12.85 | 33,843.22 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 38.81 | |
| Open | 38.07 | |
| High | 38.84 | |
| Low | 37.94 | |
| Volume | 5,941,554 | |
| Change | 0.44 | |
| Change % | 1.15 | |
| Avg Volume (20 Days) | 3,485,545 | |
| Volume/Avg Volume (20 Days) Ratio | 1.70 | |
| 52 Week Range | 33.67 - 45.93 | |
| Price vs 52 Week High | -15.50% | |
| Price vs 52 Week Low | 15.27% | |
| Range | 1.94 | |
| Gap Up/Down | -0.58 | |
Fundamentals | ||
| Market Capitalization (Mln) | 83,415 | |
| EBIDTA | 10,536,999,936 | |
| PE Ratio | 16.5699 | |
| PEG Ratio | 1.0866 | |
| WallStreet Target Price | 45.79 | |
| Book Value | 3.3940 | |
| Earnings Per Share | 2.7200 | |
| EPS Estimate Current Quarter | 0.9100 | |
| EPS Estimate Next Quarter | 0.9400 | |
| EPS Estimate Current Year | 3.9900 | |
| EPS Estimate Next Year | 4.5500 | |
| Diluted EPS (TTM) | 2.7200 | |
| Revenues | ||
| Profit Marging | 0.1459 | |
| Operating Marging (TTM) | 0.3052 | |
| Return on asset (TTM) | 0.0932 | |
| Return on equity (TTM) | 0.3878 | |
| Revenue TTM | 30,740,000,768 | |
| Revenue per share TTM | 15.1500 | |
| Quarterly Revenue Growth (YOY) | 0.0590 | |
| Quarterly Earnings Growth (YOY) | -0.3040 | |
| Gross Profit (TTM) | 19,917,000,000 | |
| Dividends | ||
| Dividend Share | 0.5900 | |
| Dividend Yield | 0.0334 | |
| Valuations | ||
| Trailing PE | 16.5699 | |
| Forward PE | 10.3199 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.9647 | |
| Revenue Enterprise Value | 3.3190 | |
| EBITDA Enterprise Value | 11.0822 | |
| Shares | ||
| Shares Outstanding | 2,039,010,048 | |
| Shares Float | 3,930,906,540 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.06 | |
| Institutions (%) | 15.13 | |
10/04 09:08 EST - reuters.com
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports
GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday.
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports
GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday.
10/01 04:48 EST - proactiveinvestors.co.uk
GSK: Does RSV jab work too well?
GSK PLC's respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by Jefferies. The jab is designed to protect older adults from RSV, a common virus that can lead to severe respiratory infections.
GSK: Does RSV jab work too well?
GSK PLC's respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by Jefferies. The jab is designed to protect older adults from RSV, a common virus that can lead to severe respiratory infections.
09/25 12:46 EST - seekingalpha.com
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.
09/23 10:47 EST - zacks.com
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
09/19 14:01 EST - zacks.com
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.
09/18 09:19 EST - reuters.com
GSK settles two California lawsuits related to heartburn drug Zantac
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer.
GSK settles two California lawsuits related to heartburn drug Zantac
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer.
09/18 07:34 EST - reuters.com
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
09/18 07:00 EST - businesswire.com
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK announces positive topline data on co-administration of AREXVY and SHINGRIX.
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK announces positive topline data on co-administration of AREXVY and SHINGRIX.
09/16 13:04 EST - prnewswire.com
Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk
Brooke Shields convenes other celebrities, influencers and patient advocates over 50 to discuss the power of aging and how to protect their health Shields directs a short film, encouraging adults 50 years of age and older to talk to their doctor or pharmacist about their risk for shingles — a disease that affects about 1 million people annually in the US — and about vaccination The partnership is part of GSK's national THRIVE@50+ campaign PHILADELPHIA , Sept. 16, 2024 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to encourage people 50 and older to embrace and protect the power they've found in aging by asking their doctor or pharmacist about their risk for shingles and about vaccination.
Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk
Brooke Shields convenes other celebrities, influencers and patient advocates over 50 to discuss the power of aging and how to protect their health Shields directs a short film, encouraging adults 50 years of age and older to talk to their doctor or pharmacist about their risk for shingles — a disease that affects about 1 million people annually in the US — and about vaccination The partnership is part of GSK's national THRIVE@50+ campaign PHILADELPHIA , Sept. 16, 2024 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to encourage people 50 and older to embrace and protect the power they've found in aging by asking their doctor or pharmacist about their risk for shingles and about vaccination.
09/16 08:00 EST - newsfilecorp.com
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief Medical Officer.
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief Medical Officer.
09/13 03:05 EST - proactiveinvestors.co.uk
GSK cancer drugs fast-tracked by Chinese
GSK PLC (LSE:GSK, NYSE:GSK) announced that its blood cancer drug Blenrep (belantamab mafodotin), in combination with two current treatments, has received Breakthrough Therapy Designation (BTD) in China. This award, granted by the National Medical Products Administration (NMPA), is aimed at speeding up the development of treatments for serious diseases that show promise in improving patient outcomes over current options.
GSK cancer drugs fast-tracked by Chinese
GSK PLC (LSE:GSK, NYSE:GSK) announced that its blood cancer drug Blenrep (belantamab mafodotin), in combination with two current treatments, has received Breakthrough Therapy Designation (BTD) in China. This award, granted by the National Medical Products Administration (NMPA), is aimed at speeding up the development of treatments for serious diseases that show promise in improving patient outcomes over current options.
09/12 12:41 EST - zacks.com
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.
09/12 07:15 EST - accesswire.com
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVac In July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that GSK has reported positive Phase 2 headline data from the seasonal influenza mRNA vaccine program.
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVac In July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that GSK has reported positive Phase 2 headline data from the seasonal influenza mRNA vaccine program.
09/12 03:43 EST - proactiveinvestors.co.uk
GSK enjoys success with mRNA flu vaccine trial
GSK PLC (LSE:GSK, NYSE:GSK) has been encouraged by the initial results of a seasonal flu vaccine using mRNA technology. Following disappointing tests for its vaccine division earlier in the week with trials of an experimental herpes treatment, the FTSE 100 pharmaceutical group said a phase II influenza vaccine has shown enough positive effects to be moved to final phase III trials.
GSK enjoys success with mRNA flu vaccine trial
GSK PLC (LSE:GSK, NYSE:GSK) has been encouraged by the initial results of a seasonal flu vaccine using mRNA technology. Following disappointing tests for its vaccine division earlier in the week with trials of an experimental herpes treatment, the FTSE 100 pharmaceutical group said a phase II influenza vaccine has shown enough positive effects to be moved to final phase III trials.
09/12 02:22 EST - reuters.com
GSK's mRNA flu vaccine programme to proceed to late-stage trials
British drugmaker GSK on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development.
GSK's mRNA flu vaccine programme to proceed to late-stage trials
British drugmaker GSK on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development.
09/11 06:11 EST - proactiveinvestors.co.uk
GSK 'clouds' blowing over suggests Berenberg
GSK PLC (LSE:GSK, NYSE:GSK) has been reiterated as a 'buy' at broker Berenberg, which sees some of the ‘clouds of doubt' that have plagued the pharma group's summer starting to ease. Zantac litigation in Delaware has been the main drag says the broker, but changes to US recommendations for Arexvy have also been a worry.
GSK 'clouds' blowing over suggests Berenberg
GSK PLC (LSE:GSK, NYSE:GSK) has been reiterated as a 'buy' at broker Berenberg, which sees some of the ‘clouds of doubt' that have plagued the pharma group's summer starting to ease. Zantac litigation in Delaware has been the main drag says the broker, but changes to US recommendations for Arexvy have also been a worry.
09/11 03:25 EST - proactiveinvestors.co.uk
GSK herpes vaccine fails in clinical trial
Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell over 1% after the drug maker said it would abandon further trials for a potential herpes vaccine after disappointing results from its clinical trials so far. The FTSE 100 group said data from the phase II part of a proof-of-concept study of the vaccine candidate showed the drug, known as GSK3943104, showed it "did not meet the study's primary efficacy objective".
GSK herpes vaccine fails in clinical trial
Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell over 1% after the drug maker said it would abandon further trials for a potential herpes vaccine after disappointing results from its clinical trials so far. The FTSE 100 group said data from the phase II part of a proof-of-concept study of the vaccine candidate showed the drug, known as GSK3943104, showed it "did not meet the study's primary efficacy objective".
09/11 02:16 EST - reuters.com
GSK's experimental HSV vaccine fails to meet main goal in trial
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
GSK's experimental HSV vaccine fails to meet main goal in trial
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
09/09 10:56 EST - zacks.com
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).
09/09 10:31 EST - proactiveinvestors.co.uk
GSK drug promotes ‘significant and clinically meaningful reduction' in asthma symptoms
British pharmaceuticals giant GSK PLC (LSE:GSK, NYSE:GSK) has presented late-breaking data at the European Respiratory Society (ERS) International Congress, highlighting a 54% reduction in severe asthma exacerbations in patients treated with depemokimab. The findings are based on the Phase III AReS study, which focused on patients with eosinophilic asthma.
GSK drug promotes ‘significant and clinically meaningful reduction' in asthma symptoms
British pharmaceuticals giant GSK PLC (LSE:GSK, NYSE:GSK) has presented late-breaking data at the European Respiratory Society (ERS) International Congress, highlighting a 54% reduction in severe asthma exacerbations in patients treated with depemokimab. The findings are based on the Phase III AReS study, which focused on patients with eosinophilic asthma.